Amydis Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $3M

  • Investors
  • 8

Amydis General Information

Description

Developer of a new class of diagnostic compounds intended for the early detection and treatment of neurodegenerative diseases. The company develops novel, patent-protected small molecule ocular tracers, which enable direct visualization of retinal disease-related molecular changes in the eye, enabling healthcare professionals to identify disorders that involve the presence of amyloid proteins for targeting the detection of early-stage Alzheimer's and other amyloid-associated diseases.

Contact Information

Website
www.amydis.com
Formerly Known As
Amydis Diagnostics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1901 Avenue of the Stars
  • Suite 200
  • Los Angeles, CA 90067
  • United States
+1 (310)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • 1901 Avenue of the Stars
  • Suite 200
  • Los Angeles, CA 90067
  • United States
+1 (310)

Amydis Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amydis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC 18-Dec-2023 $3M Completed Generating Revenue
13. Grant 14-Nov-2023 Completed Generating Revenue
12. Later Stage VC (Series A2) 29-Dec-2022 Completed Generating Revenue
11. Grant 27-Oct-2022 Completed Generating Revenue
10. Later Stage VC (Series A) 21-Apr-2022 Completed Generating Revenue
9. Grant 23-Sep-2021 Completed Generating Revenue
8. Grant 01-Sep-2021 Completed Generating Revenue
7. Grant 10-Aug-2021 Completed Generating Revenue
6. Grant 01-Jun-2021 $1.44M Completed Generating Revenue
5. Grant 23-Sep-2019 $1.5M Completed Generating Revenue
To view Amydis’s complete valuation and funding history, request access »

Amydis Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A2
Series A
To view Amydis’s complete cap table history, request access »

Amydis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a new class of diagnostic compounds intended for the early detection and treatment of neurodegenerative dis
Biotechnology
Los Angeles, CA
12 As of 2024

Barcelona, Spain
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amydis Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ona Therapeutics Venture Capital-Backed Barcelona, Spain
Volastra Venture Capital-Backed New York, NY
Loxo Oncology Formerly VC-backed Stamford, CT
Cardurion Venture Capital-Backed Burlington, MA
Ability Pharma Private Equity-Backed Barcelona, Spain
You’re viewing 5 of 13 competitors. Get the full list »

Amydis Patents

  • 56

    Total Documents Applications and Grants

  • Total Patents Families

  • 26

    Granted

  • 25

    Pending

  • Expiring in next 12 mo

Amydis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3226490-A1 N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives as fluorophors for detection of amyloid and amyloid-like proteins for diagnosis of neurodegenerative disorders Pending 15-Jul-2021
AU-2022310502-A1 N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives as fluorophors for detection of amyloid and amyloid-like proteins for diagnosis of neurodegenerative disorders Pending 15-Jul-2021
EP-4370510-A1 N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives as fluorophors for detection of amyloid and amyloid-like proteins for diagnosis of neurodegenerative disorders Pending 15-Jul-2021
US-20240325572-A1 N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives as fluorophors for detection of amyloid and amyloid-like proteins for diagnosis of neurodegenerative disorders Pending 15-Jul-2021
CA-3212704-A1 Methods of detecting systemic amyloidosis via binding to misfolded or aggregated protein Pending 12-Mar-2021 A61K49/0021
To view Amydis’s complete patent history, request access »

Amydis Executive Team (15)

Name Title Board Seat
Kerri Nelson Chief Operating Officer & Chief Commercial Officer
Ali Tafreshi Chief Technology Officer & Chief Technology Advisor
Robert Weinreb MD Chairman of Scientific Advisory Board
Ron Newbold Ph.D Chief Business Officer
Sole D'Agostino Chief Product Officer
You’re viewing 5 of 15 executive team members. Get the full list »

Amydis Board Members (9)

Name Representing Role Since
Christine Aylward Self Board Member
Franz Hefti Ph.D Self Board Member
James Khodabakhsh MD Self Board Member
Jerre Stead Self Board Member
Mervyn Turner Ph.D Self Board Member
You’re viewing 5 of 9 board members. Get the full list »

Amydis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amydis Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Michael J. Fox Foundation Limited Partner
U.S. Department of Health and Human Services Government
National institutes of Neurological Disorders and Stroke Government
National Institutes of Health Government
The National Institute on Aging (NIA) Government
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

Amydis FAQs

  • When was Amydis founded?

    Amydis was founded in 2013.

  • Who is the founder of Amydis?

    Jerry Yang Ph.D and Stella Sarraf Ph.D are the founders of Amydis.

  • Who is the CEO of Amydis?

    Stella Sarraf Ph.D is the CEO of Amydis.

  • Where is Amydis headquartered?

    Amydis is headquartered in Los Angeles, CA.

  • What is the size of Amydis?

    Amydis has 12 total employees.

  • What industry is Amydis in?

    Amydis’s primary industry is Biotechnology.

  • Is Amydis a private or public company?

    Amydis is a Private company.

  • What is Amydis’s current revenue?

    The current revenue for Amydis is .

  • How much funding has Amydis raised over time?

    Amydis has raised $14.7M.

  • Who are Amydis’s investors?

    Michael J. Fox Foundation, U.S. Department of Health and Human Services, National institutes of Neurological Disorders and Stroke, National Institutes of Health, and The National Institute on Aging (NIA) are 5 of 8 investors who have invested in Amydis.

  • Who are Amydis’s competitors?

    Ona Therapeutics, Volastra, Loxo Oncology, Cardurion, and Ability Pharma are some of the 13 competitors of Amydis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »